product summary
company name :
Ximbio
product type :
antibody
product name :
Anti-SGG [7G-2G5]
catalog :
152216
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
7G-2G5
reactivity :
human
application :
western blot, ELISA, immunocytochemistry
more info or order :
product information
Name :
Anti-SGG [7G-2G5]
Catalogue Number :
152216
Applications :
ELISA IF WB
Antigen/Gene or Protein Targets :
GSK-3 (phospho-Ser9)
Relevance :
The Monoclonal Anti-GSK-3 / Shaggy protein kinase family, Clone 7G-2G5 specifically reacts with the peptide when phosphorylated on ser9, and detects selectively the corresponding phospho-isoform of the GSK-3/Shaggy enzyme of different origins (rat, mouse, human. ) that are present in cellular extrats. The phosphorylated peptide used as an immunogen derives from the N-terminal of the shaggy polypeptide and is well conserved in comparable regions of the rat GSK-3- alpha and beta enzymes (position 8 is a T in GSK-3-beta, and position 5 is an A in GSK-3- alpha). Both insulin and EGF treatments of cells induce increased reactivity to this antibody as the result of an increased phosphorylation. This phosphorylation is associated with reduced activity of the enzyme. Glycogen synthase kinase 3 is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. Phosphorylation of a protein by GSK-3 usually inhibits the activity of its downstream target. GSK-3 is active in a number of central intracellular signaling pathways, including cellular proliferation, migration, glucose regulation, and apoptosis.
Host :
Mouse
Immunogen :
(C)SGRPRTS[phosphoS]FAE
Subclass :
IgG1 kappa
Research Area :
Apoptosis and Programmed Cell Death, Cancer, Cardiovascular, Cell Signaling & Signal Transduction, Metabolism
Notes :
Available in 100ul unit as ascites. Recommended dilutions : 1/500 - 1/5000
more info or order :
company information
Ximbio
enquiries@ximbio.com
ximbio.comreview
product type
related products
browse more products
questions and comments